ARO-DUX4

antisense oligonucleotide targeting DUX4 · Arrowhead Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARO-DUX4, covering 2026-02-06 to 2026-02-06. Get the full timeline:

Most recent: Clinical Trial Update: Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1 [Phase 1, Phase 2]

See pricing